Debate: Survival benefit of JAK2 inhibitors in Myelofibrosis

Dr. Alessandro M. Vannucchi and Dr. Heinz Gisslinger debate “Survival benefit of JAK2 inhibitors in MF: Therapy for all patients?” presented during the satellite symposium Great Debates and Clinical Considerations for the Utilization of JAK2 Inhibitors in the Treatment of Myeloproliferative Neoplasms at the 2015 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Congress held in Zagreb, Croatia, 24-26 April 2015. Within this educational activity discussion of pertinent clinical trials and review and analysis of clinical outcomes are utilized to evaluate whether JAK2 inhibitor therapy is beneficial for all patients with MF.

Earn accreditation for this activity at the following location:
http://elc.imedex.com/Shared/Services...

© 2015 Imedex, LLC.